Dr. Nikki Lurie

Tuo tilanne on juuri se, miksi CEPI suosittelee 100 päivän missionin. Se on siksi, että oli hienoa, että voisimme tehdä vaksina 327 päivänä, mutta paljon ihmisiä kuului sillä aikavälillä, ja uskomme, että maailma pitäisi olla tavoitteena vähentää sitä aikaa 100 päivänä. Joten mitä voisimme tehdä?

We have a sequence. That's great. We would then want to start thinking about, well, how would we go about making a vaccine? One of the great things we can do now is to take that sequence and try to figure out how to make the best possible, what we call antigen, the part of the vaccine that's going to create the immune response.

It used to be that we just had to do that based on the sequence. Now we can use artificial intelligence assisted methodologies to take that virus to stabilize the parts of it that create the immunity.

and create a vaccine with a new stabilized sequence. So we would be starting with AI-assisted antigen design, and then we would take those designs and we would see if they work in cells and then in animals.

Muistatko, että jopa COVID-luvun jälkeen pyysimme kehittäjäämme menemään, koska oltiin niin miettivät. Seppien suurin osa tavoitetta on, että olemme pystyneet tekemään niin paljon työtä eteenpäin kuin voimme. Yksi mahtava asia tässä on,

is that there are already antigen designs and AI-assisted antigen designs that have been developed for this virus. They have already been tested in animals and shown to be 100% protective. So we don't have to go through those steps again now because we have them.

Ja ne ovat olemassa. Ja osa koko rationeelaa luodaan niin sanottuna vaksinilibrariin, että niiden suunnitelmat ovat siellä. Me tiedämme, että ne toimivat eläimille. Joten jos sinun pitäisi tehdä vaksinia nopeasti, seuraava vaihe olisi tuoda niitä mahtajalle, jolla tiedät, että voit tehdä tätä.

On totta sanoa, että me kehitymme tämän kirjan. Ja koko SEPI 3.0 on rakentaa tämän kirjan erilaisille viruksille. Se tapahtuu vain siksi, että Hantavirus on näyttänyt itsensä huonosti. Ja se on ollut kaikissa heidän erilaisissa vahvistuslistoissaan viruksista, jotka voivat mennä eläimille ja ihmisille.

People have already used AI and designed these antigens and tested them in animals. So I would see that those are books on a library shelf that we could pull out. And so then the next steps would be to say, gee, can you manufacture this stuff?

If this were an outbreak that we were really worried about, we would have gone to a manufacturer that either we know can do this with mRNA or another rapid response platform, transfer these designs to them and say, please make us material to test in animals, to test in phase one. And if we're really worried, just continue to manufacture, perfect your manufacturing process and manufacture at scale.

We don't need to do those things, but we may find opportunities to test small parts of manufacturing processes so that we're further along for the next time. Our whole goal here is to be better set up for the next time or be better set up if this virus does something crazy.

Well, I would expect that by now that we would be doing a bunch of things at once. We would start to manufacture at scale and at risk. And this is where financing really comes in. Because you're manufacturing at scale and at risk, you don't know if it's going to work.

But you can't make up for lost time, and so you want to have those doses there. At the same time, we're testing first in animals, then we are testing for immunogenicity and safety in humans. Yes, we want to do classical clinical trials, but if you had a high mortality rate, we would do those at the same time we started vaccinating people at high risk.

Toinen asia, joka on todella tärkeä, on selittää yleisölle, mitä teemme, miksi teemme sitä, kuulemme, mitä heidän ongelmansa on, puhumme heille usein kaikesta, mitä teemme, jotta saamme turvallisuutta. Olemme tuottaneet paljon maista, jotka investoivat meihin, sekä Welcome Trust ja Gates Foundation.